<DOC>
	<DOCNO>NCT00968357</DOCNO>
	<brief_summary>SCV-07 ( Î³-D-glutamyl-L-tryptophan ) new immunomodulatory compound develop patented composition immunomodulatory use synthetic dipeptide . The efficacy SCV 07 treat chronic hepatitis C virus ( HCV ) infection expect arise drug 's ability stimulate T-helper 1 ( Th1 ) type immune response block signal transducer activator transcription 3 ( STAT3 ) mediate signal . The purpose study determine SCV-07 alone and/or SCV-07 combination ribavirin safe potentially effective treatment genotype 1 compensate chronic hepatitis C subject relapse response previous treatment course least 44 week pegylated interferon ribavirin . All subject receive 4 week SCV-07 ( Lead-in Phase ) , follow 4 week treatment SCV-07 combination ribavirin ( Combination Treatment ) .</brief_summary>
	<brief_title>Proof-of-concept Study Evaluate Safety Immunomodulatory Effects SCV 07 Monotherapy Combination With Ribavirin Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult subject must compensate liver disease Subjects must history chronic hepatitis C ( genotype 1 ) , must relapsers Subject 's HCV RNA viral load must &gt; = 300,000 IU/mL Subjects must documentation liver biopsy within last 2 year Human immunodeficiency virus ( HIV ) infection hepatitis B surface antigen ( HBsAg ) positive Clinical evidence cirrhosis Autoimmune hepatitis autoimmune/immuneactive disease Insulindependent diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>SCV-07</keyword>
	<keyword>relapsers</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>